Conatumumab

CAS No. 896731-82-1

Conatumumab( —— )

Catalog No. M36720 CAS No. 896731-82-1

Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 907 In Stock
10MG 1454 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Conatumumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Conatumumab (AMG 655) is a monoclonal agonist antibody targeting human death receptor 5 [DR5, TRAILR2] with a dissociation constant (Kd) of 1 nM for long DR5 and 0.8 nM for short DR5.
  • Description
    Conatumumab (AMG 655) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2)(Kd: 1 nM for the long form of DR5, 0.8 nM for the short form of DR5). Conatumumab induces apoptosis via caspase activation. Conatumumab can be used in the research of cancers. .
  • In Vitro
    Cell Viability Assay Cell Line:Colo205, H-2122, and MiaPaCa2 cells Concentration:0-10 μg/mL Incubation Time:24 h Result:Dose-dependently inhibited cell viability.
  • In Vivo
    Animal Model:Mice bearing Colo205, H2122, or MiaPaCa2/T2 xenograft tumors Dosage:0, 0.1, 0.3, 1, 3, 10, 30, 100 μg Administration:Intraperitoneal injection (i.p.), twice weekly.Result:Dose-dependently inhibited tumor growth.Induced caspase-3 activation in tumors (determined by IHC).
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    TNF
  • Recptor
    TNF
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    896731-82-1
  • Formula Weight
    145.65 (kDa)
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Herbst RS, et al. A first-in-human study of conatumumab in adult patients with advanced solid tumors. Clin Cancer Res. 2010 Dec 1;16(23):5883-91. ?
molnova catalog
related products
  • Hernandezine

    Hernandezine is an activator of AMPK activator and a selective reversing agent for ABCB1-mediated MDR in cancer cells.

  • Armepavine

    Armepavine exerted both in vitro and in vivo antifibrotic effects in rats, with inhibition of NF-κB, JunD and C/EBP? pathways.

  • Infliximab

    Infliximab is a humanized antibody against tumor necrosis factor α TNF-α) that is used in the treatment of Crohn's disease and rheumatoid arthritis.